Use of Apixaban and Warfarin in Patients Undergoing Procedures: Insights from ARISTOTLE (P5.002)

CONCLUSIONS: Procedures are common in patients with atrial fibrillation. The majority of procedures are non-major and non-emergent, and anticoagulation therapy is likely to be stopped peri-procedure. Overall and among emergent procedures, rates of clinical events in the first 30 days post-procedure were low and comparable between treatment groups.Study Supported by: Bristol-Myers Squibb Company and Pfizer Inc. Editorial assistance (i.e., formatting the abstract to ensure compliance with AAN guidelines) was provided by Claire Hall of Caudex Medical and was funded by Bristol-Myers Squibb Company and Pfizer Inc.Disclosure: Dr. Lopes has received personal compensation for activities with AstraZeneca, Bayer Pharmaceuticals Inc., Boehringer Ingleheim Pharmaceuticals Inc., Bristol-Myers Squibb Co., and Pfizer Inc. as a consultant. Dr. Lopes has received research support from Bristol-Myers Squibb Co., and GlaxoSmithKline Inc. Dr. Garcia has received personal compensation for activities with Bristol-Myers Squibb Co., Pfizer INc., Boehringer Ingelheim INc., Daiichi Pharmaceutical Corp., Janssen, CSL Behring, and Roche Diagnostics Corp. Dr. Wojdyla has nothing to disclose. Dr. Dorian has received personal compensation for activities with Bayer Pharmaceuticals Corp., BI, Bristol-Myers Squibb Co., and Pfizer Inc. Dr. Alexander has received personal compensation for activities with Bristol-Myers Squibb Company, Pfizer Inc, Merck & Co., Inc., Schering-Plough Corporation, AstraZeneca, Bo...

Source: Neurology - April 9, 2014 Category: Neurology Authors: Lopes, R., Garcia, D., Wojdyla, D., Dorian, P., Alexander, J., Wallentin, L., Lanas, F., Hanna, M., Held, C., Granger, C. Tags: Cerebrovascular Disease and Interventional Neurology II Source Type: research